AIVITA Biomedical Publishes Study Comparing Immune Responses and Associated Survivals Induced by Dendritic and Tumor Cell Vaccines
AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis
AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee
AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis
AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee
